[go: up one dir, main page]

EP1183011A4 - Methode, compositions pharmaceutiques et trousse de traitement de l'angine et/ou d'equivalents angineux - Google Patents

Methode, compositions pharmaceutiques et trousse de traitement de l'angine et/ou d'equivalents angineux

Info

Publication number
EP1183011A4
EP1183011A4 EP00932314A EP00932314A EP1183011A4 EP 1183011 A4 EP1183011 A4 EP 1183011A4 EP 00932314 A EP00932314 A EP 00932314A EP 00932314 A EP00932314 A EP 00932314A EP 1183011 A4 EP1183011 A4 EP 1183011A4
Authority
EP
European Patent Office
Prior art keywords
anginal
equivalents
pharmaceutical compositions
treating angina
kit related
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00932314A
Other languages
German (de)
English (en)
Other versions
EP1183011A1 (fr
Inventor
Dennis I Goldberg
Kevin Jon Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esperion LUV Development Inc
Original Assignee
Esperion LUV Development Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion LUV Development Inc filed Critical Esperion LUV Development Inc
Publication of EP1183011A1 publication Critical patent/EP1183011A1/fr
Publication of EP1183011A4 publication Critical patent/EP1183011A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP00932314A 1999-05-14 2000-05-12 Methode, compositions pharmaceutiques et trousse de traitement de l'angine et/ou d'equivalents angineux Withdrawn EP1183011A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13414099P 1999-05-14 1999-05-14
US134140P 1999-05-14
PCT/US2000/012962 WO2000069412A1 (fr) 1999-05-14 2000-05-12 Methode, compositions pharmaceutiques et trousse de traitement de l'angine et/ou d'equivalents angineux

Publications (2)

Publication Number Publication Date
EP1183011A1 EP1183011A1 (fr) 2002-03-06
EP1183011A4 true EP1183011A4 (fr) 2005-01-19

Family

ID=22461948

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00932314A Withdrawn EP1183011A4 (fr) 1999-05-14 2000-05-12 Methode, compositions pharmaceutiques et trousse de traitement de l'angine et/ou d'equivalents angineux

Country Status (6)

Country Link
EP (1) EP1183011A4 (fr)
JP (1) JP2003508349A (fr)
AU (2) AU773385B2 (fr)
CA (1) CA2373681A1 (fr)
HK (1) HK1044897A1 (fr)
WO (1) WO2000069412A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
RU2356550C2 (ru) 2001-01-26 2009-05-27 Шеринг Корпорейшн Комбинации активатора (активаторов) рецептора, активируемого пролифератором пероксисом (рапп), и ингибитора (ингибиторов) всасывания стерина и лечение заболеваний сосудов
CZ305202B6 (cs) 2001-01-26 2015-06-10 Merck Sharp & Dohme Corp. Farmaceutický prostředek
AU2002336609B2 (en) 2001-09-21 2006-08-24 Merck Sharp & Dohme Corp. Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
GB0207653D0 (en) 2002-04-03 2002-05-15 Lamellar Therapeutics Ltd Methods of using lamellar bodies for therapeutic purposes
US20040009216A1 (en) * 2002-04-05 2004-01-15 Rodrigueza Wendi V. Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
US7560449B2 (en) 2002-11-06 2009-07-14 Schering Corporation Methods and therapeutic combinations for the treatment of demyelination
MXPA05009502A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
CA2517571C (fr) 2003-03-07 2011-07-05 Schering Corporation Azetidinones substituees , procedes pour leur preparation, formulations et utilisations de celles-ci
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
GB0322448D0 (en) 2003-09-25 2003-10-29 Lamellar Therapeutics Ltd Using lamellar bodies to modify linear biological macro molecules
US9445975B2 (en) 2008-10-03 2016-09-20 Access Business Group International, Llc Composition and method for preparing stable unilamellar liposomal suspension
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
US20180177724A1 (en) * 2015-07-02 2018-06-28 The Regents Of The University Of California Site-targeted nano-liposomal nitroglycerin therapeutics
CN109902357B (zh) * 2019-01-31 2020-06-02 东南大学 一种复变差分的光滑非线性结构动响应灵敏度分析方法
CN109821021B (zh) * 2019-03-27 2020-12-25 复旦大学 P-糖蛋白抑制剂在cdx修饰的递药系统中的应用
AU2022222756A1 (en) * 2021-02-18 2023-09-14 Beren Therapeutics P.B.C. Methods for the treatment of familial heterozygous and homozygous hypercholesterolemia with cyclodextrins

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59137409A (ja) * 1983-01-27 1984-08-07 Green Cross Corp:The ベンゾジアゼピン系化合物脂肪小体製剤
DE3339861A1 (de) * 1983-11-04 1985-05-15 Bayer Ag, 5090 Leverkusen Arzneizubereitung enthaltend dihydropyridine
US4976964A (en) * 1985-04-27 1990-12-11 Bayer Aktiengesellschaft Medicament formulation containing dihydropyridines and a process for its preparation
EP0560138A1 (fr) * 1992-03-10 1993-09-15 Bayer Ag Formulations liposomales de produits pharmaceutiques et le procédé pour leur production
WO1995023592A1 (fr) * 1994-03-04 1995-09-08 The University Of British Columbia Compositions a base de liposomes et procedes de traitement de l'atherosclerose
DE19536245A1 (de) * 1994-09-30 1996-04-04 Juergen Dr Regenold Pharmazeutische Zusammensetzung
US5653998A (en) * 1994-09-12 1997-08-05 Bayer Aktiengesellschaft Injectable liposomal pharmaceutical preparations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3686025T2 (de) * 1985-05-22 1993-01-07 Liposome Technology Inc Verfahren und system zum einatmen von liposomen.
US5510389A (en) * 1994-03-02 1996-04-23 The Procter & Gamble Company Concentrated acetaminophen solution compositions
US5674488A (en) * 1994-10-07 1997-10-07 Reich; John J. Method for prevention and treatment of hyperchlolesterolemia by in vivo hydrogenation of cholesterol
US5843474A (en) * 1995-10-11 1998-12-01 Reverse Transport Licensing & Consulting, Inc. Method of dialysis treatment, and dialysis apparatus related thereto

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59137409A (ja) * 1983-01-27 1984-08-07 Green Cross Corp:The ベンゾジアゼピン系化合物脂肪小体製剤
DE3339861A1 (de) * 1983-11-04 1985-05-15 Bayer Ag, 5090 Leverkusen Arzneizubereitung enthaltend dihydropyridine
US4976964A (en) * 1985-04-27 1990-12-11 Bayer Aktiengesellschaft Medicament formulation containing dihydropyridines and a process for its preparation
EP0560138A1 (fr) * 1992-03-10 1993-09-15 Bayer Ag Formulations liposomales de produits pharmaceutiques et le procédé pour leur production
WO1995023592A1 (fr) * 1994-03-04 1995-09-08 The University Of British Columbia Compositions a base de liposomes et procedes de traitement de l'atherosclerose
US5653998A (en) * 1994-09-12 1997-08-05 Bayer Aktiengesellschaft Injectable liposomal pharmaceutical preparations
DE19536245A1 (de) * 1994-09-30 1996-04-04 Juergen Dr Regenold Pharmazeutische Zusammensetzung

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 198437, Derwent World Patents Index; Class A96, AN 1984-229071, XP002306579 *
See also references of WO0069412A1 *

Also Published As

Publication number Publication date
JP2003508349A (ja) 2003-03-04
AU773385B2 (en) 2004-05-27
EP1183011A1 (fr) 2002-03-06
WO2000069412A1 (fr) 2000-11-23
CA2373681A1 (fr) 2000-11-23
AU2004203419A1 (en) 2004-08-19
AU2004203419A2 (en) 2004-08-19
HK1044897A1 (zh) 2002-11-08
AU5005300A (en) 2000-12-05

Similar Documents

Publication Publication Date Title
EP1183011A4 (fr) Methode, compositions pharmaceutiques et trousse de traitement de l'angine et/ou d'equivalents angineux
GB0014969D0 (en) Novel method of treatment
IL160933A0 (en) Methods and compositions for treating ?cap associated diseases
DE60130043D1 (de) Grundierungszusammensetzung und Beschichtungsverfahren
DE60132732D1 (de) Primerzusammensetzung und Verbindungsverfahren
GB0110288D0 (en) Composition and treatment method
ZA200108446B (en) Novel method of treatment.
AU2001232201A1 (en) Pharmaceutical compositions and methods for treating rheumatoid arthritis
ATE355062T1 (de) Retard-zubereitungen von chinolon-antibiotika und verfahren zu ihrer herstellung
IL153359A0 (en) Peptides, compositions and methods for the treatment of burkholderia cepacia
GB0128495D0 (en) Gaming system and method of operation thereof
HUP0400296A3 (en) Method for preparation of 10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide and 10,11-dihydro-10-oxo-5h-dibenz/b,f/azepine-5-carboxamide
GB0126643D0 (en) Composition and process
ZA200203435B (en) Method and compositions for treating pulmonary diseases.
AU6137801A (en) Method and composition for the treatment of angiogenesis
IL161057A0 (en) Composition and method for minimizing or avoiding adverse effects of vesicants
EP1163340A4 (fr) Compositions et methodes de modification de l'expression genique
AU5565401A (en) Materials and methods for the treatment of depression
GB0008921D0 (en) Method of treatment
GB9924752D0 (en) Method of construction
GB2346869B (en) Improved carton and method of construction therefor
AU2002342188A1 (en) Methods and compositions for treating flavivirus-mediated disease
ZA200007816B (en) Composition and method for the treatment of concrete and masonry.
GB0107033D0 (en) Method and composition
AU2002353915A1 (en) Methods and compositions for treating rotavirus-mediated disease

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011213

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ESPERION LUV DEVELOPMENT INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20041208

17Q First examination report despatched

Effective date: 20050609

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051220

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1044897

Country of ref document: HK